Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | APP | P05067 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.70 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL579312 | 0.89 | SIRT2 (0.67) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Methyl Salicylate SCHEMBL810913 | 0.85 | KMT2A (0.61) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Benzoic Acid SCHEMBL1008425 | 0.84 | ALDH1A1 (0.91) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL29349574 | 0.84 | — | — | |
| Niacin SCHEMBL30844065 | 0.84 | — | — | |
| Niacin SCHEMBL1433 | 0.84 | — | — | |
| Niacin SCHEMBL3081560 | 0.84 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL28292236 | 0.84 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL29396199 | 0.84 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL150011 | 0.84 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | claimed |
| EP-2665730-B1 | COMPOUNDS WITH SUPER-ASPIRIN EFFECTS | THE PROVOST FELLOWS FOUND SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV T (IE) | 2019-07-24 | — | — | EP | disclosed |
| US-9670223-B2 | Compounds with super-aspirin effects | SOLVOTRIN THERAPEUTICS LTD. (IE) | 2017-06-06 | — | — | US | disclosed |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | UNIV OHIO (US) | 2016-08-04 | — | — | US | disclosed |
| US-9326972-B2 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150291615-A1 | COMPOUNDS WITH SUPER-ASPIRIN EFFECTS | SOLVOTRIN THERAPEUTICS LTD (IE) | 2015-10-15 | — | — | US | disclosed |
| US-20140024681-A1 | COMPOUNDS WITH SUPER-ASPIRIN EFFECTS | The Provost,Fellowws, Foudation Scholars, and the Other Members of Board, of the College of the Holy (IE) | 2014-01-23 | — | — | US | disclosed |
| EP-2665730-A1 | COMPOUNDS WITH SUPER-ASPIRIN EFFECTS | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) | 2013-11-27 | — | — | EP | disclosed |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| WO-2012098237-A1 | COMPOUNDS WITH SUPER-ASPIRIN EFFECTS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2012-07-26 | — | — | WO | disclosed |
| EP-2399578-A1 | Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors | The Interthyr Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | OHIO UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| EP-1896015-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | The Interthyr Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124676-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | THE INTERTHYR CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | BENAVIDES-PERALTA, URUGUAYSITO LORELEY (UY) | 2006-09-21 | — | — | US | disclosed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291615-A1 | COMPOUNDS WITH SUPER-ASPIRIN EFFECTS | HAO2, SCO2, AOC2 | ALDH1A1 581/4885APP 4630/4885GAA 4527/4885 |
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | TLR3, IRF3, TLR4 | ALDH1A1 3364/4885APP 2349/4885GAA 4730/4885 |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | IRF3, TLR3, TLR4 | ALDH1A1 3709/4885APP 3351/4885GAA 4660/4885 |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | IRF3, TLR3, TLR4 | ALDH1A1 3709/4885APP 3351/4885GAA 4660/4885 |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | STAT3, STAT6, TLR3 | ALDH1A1 2982/4885APP 4660/4885GAA 4770/4885 |
| US-20140024681-A1 | COMPOUNDS WITH SUPER-ASPIRIN EFFECTS | HAO2, SCO2, NOS2 | ALDH1A1 649/4885APP 4663/4885GAA 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.